Phase I dose escalation study of TAA013, a trastuzumab antibody drug conjugate in patients with recurrent her2 positive metastatic Breast Cancer
Latest Information Update: 25 Jan 2021
At a glance
- Drugs TAA-013 (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- 25 Jan 2021 New trial record
- 11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium